Monte Rosa Therapeutics Profit Margin

As of the most recent data (March 2026), GLUE shows a profit margin of -302.69%. That compares with 3.86% in the prior-year period — down 7945.8% year over year. That is below the Healthcare sector average of 15.29%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GLUE's profit margin is now -302.69% (was 3.86%) — a 7945.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Monte Rosa Therapeutics is outperforming or lagging.

The Healthcare sector average profit margin is about 15.29%. Monte Rosa Therapeutics is at -302.69%, which is lower that average. That is roughly 2079.3% below the sector mean. Use the comparison chart on this page to see how GLUE stacks up against individual peers as well.

That compares with 3.86% in the prior-year period — down 7945.8% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Monte Rosa Therapeutics with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Monte Rosa Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -302.69%) with ownership activity and broader fundamentals.